ReviewCancers2025
Stereotactic Body Radiation Therapy (SBRT) for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis for untreated renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC TT) is poor, and the only curative treatment option is extirpative surgery. However, radical nephrectomy with IVC thrombectomy is associated with high rates of morbidity and mortality. Historically, RCC was considered radioresistant, but it appears to be sensitive to higher doses per fraction. Stereotactic body radiation therapy (SBRT), which delivers high ablative radiation doses to focal targets, has been shown to be an effective treatment option for both non-metastatic and metastatic RCC. Emerging data also suggest its role in the management of RCC with IVC TT. This article reviews the available evidence on the use of SBRT in RCC patients with IVC TT, considering its application as curative, palliative, and neoadjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.